A Randomized Multicenter, Open-Label Phase II/III Study to Evaluate the Safety and Efficacy of Disitamab Vedotin Combined With Cadonilimab in Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Adenocarcinoma Who Have Progressed on First-line Therapy
Latest Information Update: 08 Apr 2024
At a glance
- Drugs Cadonilimab (Primary) ; Disitamab vedotin (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors RemeGen
Most Recent Events
- 01 Apr 2024 Status changed from not yet recruiting to recruiting.
- 29 Jan 2024 New trial record